Does IMAAVY’s Approval and Ongoing Talc Verdict Meaningfully Shift the Bull Case for Johnson & Johnson (JNJ)?

• In August 2026, Johnson & Johnson received FDA approval for IMAAVY (nipocalimab-aahu) to treat warm autoimmune hemolytic anemia in patients 12 and older, while a Louisiana jury also found the company partly liable in a talc-related mesothelioma case, assigning it over US$1.20 million of a US$10.00 million verdict.
• The combination of expanding its rare disease portfolio with IMAAVY and ongoing talc litigation underlines how Johnson & Johnson’s innovation efforts continue alongside persistent legal exposure.
• We’ll now examine how the IMAAVY approval for warm autoimmune hemolytic anemia could reshape Johnson & Johnson’s existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Johnson & Johnson Investment Narrative Recap

To own Johnson & Johnson today, you need to believe its diversified medicines and MedTech portfolio can offset patent, pricing and legal headwinds, while funding ongoing innovation. The IMAAVY approval adds to the rare disease franchise and could support near term sentiment, but the talc verdict highlights that litigation remains a key overarching risk that can periodically affect cash flow and headline risk, even if this single award is not financially material in isolation.

Among recent announcements, the IMAAVY approval for warm autoimmune hemolytic anemia is most relevant, because it builds directly on the same FcRn platform already in use for generalized myasthenia gravis. This reinforces the idea that pipeline execution in Immunology can help counterbalance pressures such as STELARA biosimilar competition and tariff related margin strain, while investors weigh that potential against the persistent uncertainty around talc related liabilities.

Yet while innovation like IMAAVY can support the story, the unresolved talc litigation still presents a risk investors should be aware of, including ...

Read the full narrative on Johnson & Johnson (it's free!)

Johnson & Johnson's narrative projects $120.5 billion revenue and $28.6 billion earnings by 2029. This requires 7.2% yearly revenue growth and a $7.6 billion earnings increase from $21.0 billion today.

Uncover how Johnson & Johnson's forecasts yield a $270.59 fair value, in line with its current price.

Exploring Other Perspectives

Compared with the baseline, the most bearish analysts were assuming only about 5.9% annual revenue growth and earnings of roughly US$22.6 billion by 2029, so if you worry that MedTech robotics like OTTAVA could stumble at launch timelines or adoption, this new IMAAVY news might be exactly the kind of development that forces everyone to revisit both the pessimistic and more optimistic cases.

Explore 9 other fair value estimates on Johnson & Johnson - why the stock might be worth 16% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Johnson & Johnson research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Johnson & Johnson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Johnson & Johnson's overall financial health at a glance.

Seeking Other Investments?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Outshine the giants: these 19 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.